DexCom boosted its 2026 non-GAAP operating margin guidance to 23%-23.5% after reporting strong Q1 revenue growth and product momentum. Management credited expanded coverage for type 2 non-insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results